MFMargaret Fletcher

Margaret Fletcher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Margaret Fletcher has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Parents’ perceptions of influenza and why they accept or decline the nasal vaccine for their child

    by Phoebe Moulsdale, Aimee Grant, Margaret Fletcher, Adam Finn

    Background Nasal influenza vaccine is offered each year to all children from age two to higher age groups. There is little UK research on whether parents support this vaccination programme. Aim The aim of this study was to explore parents’ perceptions of influenza as an illness in children and why they decide to accept or decline nasal influenza vaccine for their child. Method A survey was first distributed to parents via a single primary school. Ten parents were then sampled in semi-structured interviews. From the survey, 91% (n=78) of the parents favoured routine vaccinations but only 47% (n=40) were supportive of nasal influenza vaccination. Findings From the interviews, reasons highlighted for accepting or declining the vaccine concerned the importance of trust, community responsibility, controllability and the perception of risk. Conclusion Parents who typically support vaccination may doubt the necessity of a influenza vaccination for their child. This may reduce uptake and undermine the programme.


  • Open Access

    The TARGET cohort study protocol: a prospective primary care cohort study to derive and validate a clinical prediction rule to improve the targeting of antibiotics in children with respiratory tract illnesses

    by Niamh M Redmond, Rachel Davies, Hannah Christensen, Peter S Blair, Andrew M Lovering, John P Leeming, Peter Muir, Barry Vipond, Hannah Thornton, Margaret Fletcher, et al.

    Children with respiratory tract infections are the single most frequent patient group to make use of primary care health care resources. The use of antibiotics remains highly prevalent in young children, but can lead to antimicrobial resistance as well as reinforcing the idea that parents should re-consult for similar symptoms. One of the main drivers of indiscriminate antimicrobial use is the lack of evidence for, and therefore uncertainty regarding, which children are at risk of poor outcome. This paper describes the protocol for the TARGET cohort study, which aims to derive and validate a clinical prediction rule to identify children presenting to primary care with respiratory tract infections who are at risk of hospitalisation. The TARGET cohort study is a large, multicentre prospective observational study aiming to recruit 8,300 children aged ≥3 months and <16 years presenting to primary care with a cough and respiratory tract infection symptoms from 4 study centres (Bristol, London, Oxford and Southampton). Following informed consent, symptoms, signs and demographics will be measured. In around a quarter of children from the Bristol centre, a single sweep, dual bacterial-viral throat swab will be taken and parents asked to complete a symptom diary until the child is completely well or for 28 days, whichever is sooner. A review of medical notes including clinical history, re-consultation and hospitalisations will be undertaken. Multivariable logistic regression will be used to identify the independent clinical predictors of hospitalisation as well as the prognostic significance of upper respiratory tract microbes. The clinical prediction rule will be internally validated using various methods including bootstrapping. The clinical prediction rule for hospitalisation has the potential to help identify a small group of children for hospitalisation and a much larger group where hospitalisation is very unlikely and antibiotic prescribing would be less warranted. This study will also be the largest natural history study to date of children presenting to primary care with acute cough and respiratory tract infections, and will provide important information on symptom duration, re-consultations and the microbiology of the upper respiratory tract.


  • CHILDHOOD EMPYEMA: LIMITED POTENTIAL IMPACT OF 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE

    by Margaret Fletcher, John Leeming, Keith Cartwright, Adam Finn

    During 2003-2004, locally presenting pleural empyema cases in children increased 3-fold. Antigen analysis of empyema fluid identified Streptococcus pneumoniae in 27 of 29 cases for whom samples were available and capsular polysaccharide type 1 in 18 of these. Use of a conjugate vaccine without serotype 1 antigen would have had limited impact on this morbidity in our region.